My Profile Delegates Directory Reference Hub Events Logout

Transparency Statement

Financial Year: 2024

The European Academy of Paediatrics (EAP) is committed to transparency, independence, and good governance for healthcare professional organisations.

In accordance with EMA requirements, EAP publicly discloses the following information regarding its funding sources and financial structure.

 

1. Funding Sources

 

Non-industry funding sources include:

  • Membership fees

  • Specialty and certification examination fees

  • Conference and educational event participation fees

  • Other non-industry income

 

Industry funding sources include:

  • Educational and scientific grants

  • Support related to congresses and events

  • Other industry-related contributions received in accordance with EAP’s Sponsorship and Independence Policy

 

2. Proportion of Industry and Non-Industry Funding

For the financial year 2024, EAP’s overall income was composed of the following:

 

  • Industry funding: 56.93%

  • Non-industry funding: 43.07%

 

These proportions are calculated based on EAP’s total annual income for the 2024 financial year.

 

3. Highest Contribution from a Single Company

In 2024, the highest contribution received from a single company represented 20.33% of EAP’s total annual income.

 

4. Independence and Governance

EAP regulates its relationships with sponsors and industry partners through a publicly available Sponsorship and Independence Policy, which sets out principles to safeguard the organisation’s scientific, educational, and organisational independence.

Formal written agreements are concluded where applicable, and no sponsor exercises influence over EAP’s governance, strategic decisions, scientific content, or policy positions.

 

5. Updates

This transparency information is reviewed and updated annually in line with EAP’s financial reporting cycle.

close menu icon

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

  • BERTHOLD KOLETZKO
Read more